3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
12
Terminated
2
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Gastrointestinal
2
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Leukemia
7
Leukemia, Myeloid, Chronic-Phase
6
Leukemia, Myeloid
2
Gastrointestinal Stromal Tumors
2
Bone Marrow Diseases
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms by Histologic Type
1
Neoplasms
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myeloproliferative Disorders
1
Leukemia, Myeloid, Acute
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Blast Crisis
1
Interventions
Imatinib Mesylate
10
Sunitinib
4
spartalizumab
2
pembrolizumab
2
nilotinib
2
Surveys and Questionnaires
2
tanespimycin
1
ribociclib
1
pexidartinib
1
pazopanib
1
olaratumab
1
oblimersen
1
motexafin lutetium
1
masitinib
1
guadecitabine
1
ferric carboxymaltose
1
famitinib
1
epacadostat
1
Surgical Procedures, Operative
1
Quality of Life
1
Observation
1
Iron-Dextran Complex
1
Indocyanine Green
1
Immunoglobulin G
1
Fluorescein
1
Disulfides
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Terminated
×
Gastrointestinal Stromal Tumors
×
nilotinib
×
Clear all
NCT00751036
2014-03-26
MACS0375
Novartis
Phase 3
Terminated
94 enrolled
10 charts
NCT00782834
2013-04-22
07060
Fox Chase Cancer Center
Phase 2
Terminated
13 enrolled
8 charts